Travere Therapeutics (TVTX) Asset Writedowns and Impairment (2015 - 2022)

Travere Therapeutics has reported Asset Writedowns and Impairment for 7 years, with the latest figure at -$1.0 million in Q4 2022.

• For the quarter ending Q4 2022, Asset Writedowns and Impairment fell 17.96% year-over-year to -$1.0 million; the trailing twelve-month figure through Dec 2022 stood at $1.0 million (up 108.63% YoY), and the FY2025 full-year result was $684000.0, down 75.74% from the prior year.
• Asset Writedowns and Impairment for Q4 2022 stood at -$1.0 million, down from $329000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $25.5 million in Q1 2019, with the low at -$24.0 million in Q4 2019.
• Historically, Asset Writedowns and Impairment has averaged $475454.5 across 4 years, with a median of $475000.0 in 2021.
• Annual changes were most pronounced in 2020 — Asset Writedowns and Impairment soared 109.26% — and 2021, when it slumped 139.28%.
• Travere Therapeutics' Asset Writedowns and Impairment stood at -$24.0 million in 2019, then jumped by 109.26% to $2.2 million in 2020, then tumbled by 139.28% to -$874000.0 in 2021, then fell by 17.96% to -$1.0 million in 2022.
• The last three Asset Writedowns and Impairment figures came in at -$1.0 million (Q4 2022), $329000.0 (Q3 2022), and $792000.0 (Q2 2022), per Business Quant data.